Roth Capital maintained a Buy rating on Exact Sciences (NASDAQ: EXAS), and cut the price target to $12.00 (from $15.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Exact Sciences (EXAS) Misses Q3 EPS by 1cOctober 29, 2015 8:25 AM Cologuard® Growth Trajectory Increases to 34,000 Completed Tests, Generates $12.6M in Revenue in Third Quarter 2015October 29, 2015 5:00 AM UPDATE: Trading Radar for 10/29: Aetna (AET), LinkedIn (LNKD), Baidu (BIDU), ConocoPhillips (COP), MGM Resorts (MGM), Deckers (DECK) ReportOctober 28, 2015 2:53 PM Exact Sciences (EXAS) Says New Study Bolsters Cologuard's PerformanceOctober 28, 2015 2:48 PM New Study Bolsters Cologuard’s Performance in Detecting Colorectal Cancer and Ability to Improve Access to ScreeningOctober 28, 2015 2:43 PM